Cytokine profiles by peripheral blood monocytes are associated with changes in behavioral symptoms following immune insults in a subset of ASD subjects: an inflammatory subtype?

Journal of Neuroinflammation

Amy L Davidow¹  Lee Geng²  Harumi Jyonouchi² 

[1] Departments of Public Health, New Jersey Medical School-Rutgers University, 185 South Orange Ave., Newark 07101, NJ, USA;Department of Pediatrics, Saint Peter¿s University Hospital, 254 Easton Ave., New Brunswick 08873, NJ, USA

关键词: Neuroimmune network;    Cytokines;    GI symptoms;    NFA;    inflammatory subtype;    ASD;   

Others  :  1150484
DOI  :  10.1186/s12974-014-0187-2

 received in 2014-06-12, accepted in 2014-10-16,  发布年份 2014

【 摘 要 】

Background

Some children with autism spectrum disorders (ASD) are characterized by fluctuating behavioral symptoms following immune insults, persistent gastrointestinal (GI) symptoms, and a lack of response to the first-line intervention measures. These children have been categorized as the ASD-inflammatory subtype (ASD-IS) for this study. We reported a high prevalence of non-IgE mediated food allergy (NFA) in young ASD children before, but not all ASD/NFA children reveal such clinical features of ASD-IS. This study addressed whether behavioral changes of ASD-IS are associated with innate immune abnormalities manifested in isolated peripheral blood (PB) monocytes (Mo), major innate immune cells in the PB.

Methods

This study includes three groups of ASD subjects (ASD-IS subjects (N = 24), ASD controls with a history of NFA (ASD/NFA (N = 20), and ASD/non-NFA controls (N = 20)) and three groups of non-ASD controls (non-ASD/NFA subjects (N = 16), those diagnosed with pediatric acute onset-neuropsychiatric syndrome (PANS, N = 18), and normal controls without NFA or PANS (N = 16)). Functions of purified PB Mo were assessed by measuring the production of inflammatory and counter-regulatory cytokines with or without stimuli of innate immunity (lipopolysaccharide (LPS), zymosan, CL097, and candida heat extracts as a source of ?-lactam). In ASD-IS and PANS subjects, these assays were done in the state of behavioral exacerbation (`flare¿) and in the stable (`non-flare¿) condition. ASD-IS children in the `flare¿ state revealed worsening irritability, lethargy and hyperactivity.

Results

`Flare¿ ASD-IS PB Mo produced higher amounts of inflammatory cytokines (IL-1? and IL-6) without stimuli than `non-flare¿ ASD-IS cells. With zymosan, `flare¿ ASD-IS cells produced more IL-1? than most control cells, despite spontaneous production of large amounts of IL-1ß. Moreover, `flare¿ ASD-IS Mo produced less IL-10, a counterregulatory cytokine, in response to stimuli than `non-flare¿ cells or other control cells. These changes were not observed in PANS cells.

Conclusions

We observed an imbalance in the production of inflammatory (IL-1ß and IL-6) and counterregulatory (IL-10) cytokines by `flare¿ ASD-IS monocytes, which may indicate an association between intrinsic abnormalities of PB Mo and changes in behavioral symptoms in the ASD-IS subjects.

【 授权许可】

   
2014 Jyonouchi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Jeste SS, Geschwind DH: Disentangling the heterogeneity of autism spectrum disorder through genetic findings. Nat Rev Neurol 2014, 10:74-81.
• [2]Carvill GL, Mefford HC: Microdeletion syndromes. Curr Opin Genet Dev 2013, 23:232-239.
• [3]Carr EG, Owen-Deschryver JS: Physical illness, pain, and problem behavior in minimally verbal people with developmental disabilities. J Autism Dev Disord 2007, 37:413-424.
• [4]Akins RS, Krakowiak P, Angkustsiri K, Hertz-Picciotto I, Hansen RL: Utilization patterns of conventional and complementary/alternative treatments in children with autism spectrum disorders and developmental disabilities in a population-based study. J Dev Behav Pediatr 2014, 35:1-10.
• [5]Hendren RL: Autism: biomedical complementary treatment approaches. Child Adolesc Psychiatr Clin N Am 2013, 22:443-456. vi
• [6]Rossignol DA: Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiatry 2009, 21:213-236.
• [7]Jyonouchi H, Geng L, Streck DL, Toruner GA: Children with autism spectrum disorders (ASD) who exhibit chronic gastrointestinal (GI) symptoms and marked fluctuation of behavioral symptoms exhibit distinct innate immune abnormalities and transcriptional profiles of peripheral blood (PB) monocytes. J Neuroimmunol 2011, 238:73-80.
• [8]Jyonouchi H, Geng L, Cushing-Ruby A, Quraishi H: Impact of innate immunity in a subset of children with autism spectrum disorders: a case control study. J Neuroinflammation 2008, 5:52. BioMed Central Full Text
• [9]Jyonouchi H, Geng L, Streck DL, Toruner GA: Immunological characterization and transcription profiling of peripheral blood (PB) monocytes in children with autism spectrum disorders (ASD) and specific polysaccharide antibody deficiency (SPAD): case study. J Neuroinflammation 2012, 9:4. BioMed Central Full Text
• [10]Rebane A, Akdis CA: MicroRNAs: Essential players in the regulation of inflammation. J Allergy Clin Immunol 2013, 132:15-26.
• [11]Guedes J, Cardoso AL, De Lima MC P: Involvement of microRNA in microglia-mediated immune response. Clin Dev Immunol 2013, 2013:186872.
• [12]Tse MT: Neuroimmunology: uncovering new roles for microRNAs and TLRs. Nat Rev Neurosci 2012, 13:448.
• [13]Swedo SE, Leckman JF, Rose NR: From research subgroup to clinical syndrome: modifying the PANDAS criteria to describe PANS (Pediatric Acute-onset Neuropsychiatric Syndrome). Peditrics Ther 2012, 2:113.
• [14]Jyonouchi H: Non-IgE mediated food allergy - update of recent progress in mucosal immunity. Inflamm Allergy Drug Targets 2012, 11:382-396.
• [15]Aman MG, Singh NN, Stewart AW, Field CJ: The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985, 89:485-491.
• [16]Owens JA, Spirito A, McGuinn M: The children¿s sleep habits questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children. Sleep 2000, 23:1043-1051.
• [17]Sparrow SBCD, Vineland DV: Adaptive behavior scales survey form manual. Am Guid Serv 1985, 1985:1985.
• [18]Breau LM, McGrath PJ, Camfield CS, Finley GA: Psychometric properties of the non-communicating children¿s pain checklist-revised. Pain 2002, 99:349-357.
• [19]Boyce JA, Assa¿ad A, Burks AW, Jones SM, Sampson HA, Wood RA, Plaut M, Cooper SF, Fenton MJ, Arshad SH, Beck LA, Byrd-Bredbenner C, Camargo CA Jr, Eichenfild L, Furuta TG, Hanifin JM, Jones C, Kraft M, Levy BD, Lieberman P, Luccioli S, McCall KM, Schneider LC, Simon RA, Simons FE, Teach SJ, Yawn BP, Schwaninger JM: Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010, 126:S1-S58.
• [20]Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, Burks AW, Chehade M, Collins MH, Dellon ES, Dohil R, Falk GW, Gonsalves N, Gupta SK, Katzka DA, Lucendo AJ, Markowitz JE, Noel RJ, Odze RD, Putnam PE, Richter JE, Romero Y, Ruchelli E, Sampson HA, Schoepfer A, Shaheen NJ, Sicherer SH, Spechler S, Spergel JM, Straumann A, et al.: Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011, 128:3-20. e26. quiz 21¿22
• [21]Butrus S, Portela R: Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am 2005, 18:485-492. v. Review
• [22]Nassef M, Shapiro G, Casale TB: Identifying and managing rhinitis and its subtypes: allergic and nonallergic components¿a consensus report and materials from the Respiratory and Allergic Disease Foundation. Curr Med Res Opin 2006, 22:2541-2548.
• [23]Guidelines for the diagnosis and management of asthma-summary report 2007 J Allergy Clin Immunol 2007, 120:S94-S138.
• [24]Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, Kumararatne D, Harville TO, Hesterberg P, Koleilat M, McGhee S, Perez EE, Raasch J, Scherzer R, Schroeder H, Seroogy C, Huissoon A, Sorensen RU, Katial R: Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the basic and clinical immunology interest section of the american academy of allergy, asthma & immunology. J Allergy Clin Immunol 2012, 130:S1-S24.
• [25]Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B: Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology 2005, 51:77-85.
• [26]Enstrom AM, Onore CE, Van de Water JA, Ashwood P: Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immun 2010, 24:64-71.
• [27]Benros ME, Mortensen PB, Eaton WW: Autoimmune diseases and infections as risk factors for schizophrenia. Ann N Y Acad Sci 2012, 1262:56-66.
• [28]Meyer U, Feldon J, Dammann O: Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res 2011, 69:26R-33R.
• [29]Michel M, Schmidt MJ, Mirnics K: Immune system gene dysregulation in autism and schizophrenia. Dev Neurobiol 2012, 72:1277-1287.
• [30]Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B: Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011, 70:663-671.
• [31]Watanabe Y, Someya T, Nawa H: Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin Neurosci 2010, 64:217-230.
• [32]Josefowicz SZ, Lu LF, Rudensky AY: Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012, 30:531-564.
• [33]Lechtenberg BC, Mace PD, Riedl SJ: Structural mechanisms in NLR inflammasome signaling. Curr Opin Struct Biol 2014, 29C:17-25.
• [34]Federici S, Martini A, Gattorno M: The central role of anti-IL-1 blockade in the treatment of monogenic and multi-factorial autoinflammatory diseases. Front Immunol 2013, 4:351.
• [35]Tanaka T, Narazaki M, Ogata A, Kishimoto T: A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin Immunol 2014, 26:88-96. Volume 8
• [36]Serada S, Fujimoto M, Mihara M, Koike N, Ohsugi Y, Nomura S, Yoshida H, Nishikawa T, Terabe F, Ohkawara T, Takahashi T, Ripley B, Kimura A, Kishimoto T, Naka T: IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2008, 105:9041-9046.
• [37]Smith SE, Li J, Garbett K, Mirnics K, Patterson PH: Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007, 27:10695-10702.
• [38]Kirsten TB, Lippi LL, Bevilacqua E, Bernardi MM: LPS exposure increases maternal corticosterone levels, causes placental injury and increases IL-1Beta levels in adult rat offspring: relevance to autism. PLoS One 2013, 8:e82244.
• [39]Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J: Biology of interleukin-10. Cytokine Growth Factor Rev 2010, 21:331-344.